Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    ARST0921
Show Display Options
Rank Status Study
1 Active, not recruiting Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Conditions: Adult Rhabdomyosarcoma;   Childhood Alveolar Rhabdomyosarcoma;   Childhood Anaplastic Rhabdomyosarcoma;   Childhood Mixed Alveolar Rhabdomyosarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma
Interventions: Drug: Vinorelbine Tartrate;   Drug: Cyclophosphamide;   Biological: Bevacizumab;   Drug: Temsirolimus;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years